Devising a strategy for prevention of malaria in pregnant women in the Asia Pacific

Chico, R Matthew; Cano, Jorge

doi:10.1016/s1473-3099(19)30390-1

Cited by 3 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The global effort to end the preventable death of the mother caused by the comorbidity of Plasmodium parasitaemia and helminthiasis requires a concerted global health leadership and commitment [160,161]. Sustainable implementation of the water, sanitation, and hygiene (WASH) programs, combined with improving the practice of early initiation of effective intermittent preventive therapy, can avert unintended health consequences as a result of malaria in pregnancy [162][163][164][165][166][167].…”

Section: Ending Preventable Maternal Mortality Due To Malarial and He...mentioning

confidence: 99%

Malaria and Helminthic Co-Infection during Pregnancy in Sub-Saharan Africa: A Systematic Review and Meta-Analysis

Boltena

El‐Khatib

Kebede

et al. 2022

IJERPH

View full text Add to dashboard Cite

Malaria and helminthic co-infection during pregnancy causes fetomaternal haemorrhage and foetal growth retardation. This study determined the pooled burden of pregnancy malaria and helminthic co-infection in sub-Saharan Africa. CINAHL, EMBASE, Google Scholar, Scopus, PubMed, and Web of Science databases were used to retrieve data from the literature, without restricting language and publication year. The Joanna Briggs Institute’s critical appraisal tool for prevalence studies was used for quality assessment. STATA Version 14.0 was used to conduct the meta-analysis. The I2 statistics and Egger’s test were used to test heterogeneity and publication bias. The random-effects model was used to estimate the pooled prevalence at a 95% confidence interval (CI). The review protocol has been registered in PROSPERO, with the number CRD42019144812. In total, 24 studies (n = 14,087 participants) were identified in this study. The pooled analysis revealed that 20% of pregnant women were co-infected by malaria and helminths in sub-Saharan Africa. The pooled prevalence of malaria and helminths were 33% and 35%, respectively. The most prevalent helminths were Hookworm (48%), Ascaris lumbricoides (37%), and Trichuris trichiura (15%). Significantly higher malaria and helminthic co-infection during pregnancy were observed. Health systems in sub-Saharan Africa must implement home-grown innovative solutions to underpin context-specific policies for the early initiation of effective intermittent preventive therapy.

show abstract

Section: Ending Preventable Maternal Mortality Due To Malarial and He...mentioning

confidence: 99%

Malaria and Helminthic Co-Infection during Pregnancy in Sub-Saharan Africa: A Systematic Review and Meta-Analysis

Boltena

El‐Khatib

Kebede

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Placental malaria occurs in 16%–63% of pregnant women (Darmstadt et al, 2011) with malaria and is the leading global cause of maternal anemia, low birth weight, preterm delivery, stillbirths, and miscarriages (Goldenberg et al, 2010). Each year, approximately 30–35 million women become pregnant in malaria‐endemic areas of Africa, and similar numbers of women can be exposed to malaria in Asia, Oceania, and South America (Chico & Cano, 2019; World Health Organization (WHO), 2021). Unfortunately, due to a shortage of safety data on pregnant women for most of the currently recommended antimalarial drugs, there are limited treatment options for this vulnerable population, particularly in the first trimester.…”

Section: Introductionmentioning

confidence: 99%

Integration and application of new approach methodologies in assessing the developmental hazards: Case study with an antimalarial drug

Demarta‐Gatsi

Jamalpoor²,

Hendriks³

et al. 2023

Birth Defects Research

View full text Add to dashboard Cite

“…The latest World Health Organization (WHO) World Malaria Report [ 1 ] states that in 2020 there were an estimated 241 million cases of infection in 87 malaria endemic countries, resulting in 627,000 deaths, and more than a third of pregnant women in 33 African countries with moderate to high transmission had malaria. Data from regions outside of Africa are scarce, but more than 90 million pregnant women were estimated to be at risk of malaria in the Asia–Pacific region [ 2 ]. These are estimates and subject to change as malaria elimination progresses.…”

Section: Introductionmentioning

confidence: 99%

“…Despite the WHO recommendation, ACT is being adopted by national guidelines as first-line treatment for first trimester pregnancy in some malaria-endemic countries [ 17 ]. Moreover, it is important to point out that the malaria epidemiological context outside of Africa poses unique challenges for pregnant women at risk of P. vivax malaria [ 2 , 15 ]. The blood-stage of P. vivax infection can in most regions of the world still be treated with chloroquine, a drug that is considered safe in pregnancy [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Re-orienting anti-malarial drug development to better serve pregnant women

Gaaloul

Tornesi

Lebus³

et al. 2022

Malar J

View full text Add to dashboard Cite

Malaria is one of the most serious infectious diseases affecting predominantly low- and middle-income countries, where pregnant women are among the populations at risk. There are limited options to prevent or treat malaria in pregnancy, particularly in the first trimester, and existing ones may not work optimally in areas where the threat of drug resistance is rising. As malaria elimination is a key goal of the global health community, the inclusion of pregnant women in the adult population to protect from malaria will be key to achieving success. New, safe, and effective options are needed but it can take decades of evidence-gathering before a medicine is recommended for use in pregnancy. This is because pregnant women are typically not included in pre-registration clinical trials due to fear of causing harm. Data to support dosing and safety in pregnancy are subsequently collected in post-licensure studies. There have been growing calls in recent years that this practice needs to change, amplified by the COVID-19 pandemic and increasing public awareness that newly developed medicines generally cannot be administered to pregnant women from the onset. The development of new anti-malarials should ensure that data informing their use in pregnancy and breastfeeding are available earlier. To achieve this, a mindset change and a different approach to medications for pregnant women are needed. Changes in non-clinical, translational, and clinical approaches in the drug development pathway, in line with recent recommendations from the regulatory bodies are proposed in this Comment. The new approach applies to any malaria-endemic region, regardless of the type of Plasmodium responsible for malaria cases. By incorporating intentional and systematic data collection from pre-registration stages of development through post-licensure, it will be possible to inform on the benefit/risk balance of a new anti-malarial earlier and help ensure that the needs of pregnant individuals are addressed in a more timely and equitable manner in the future.

show abstract

Devising a strategy for prevention of malaria in pregnant women in the Asia Pacific

Abstract: community-level benefits of decreased transmission. A complete evaluation of the impact of a targeted prevention effort must compare the risk of rebound with the potential for decreased transmission and the individual-level benefits of malaria prevention.

Cited by 3 publications

References 13 publications

Malaria and Helminthic Co-Infection during Pregnancy in Sub-Saharan Africa: A Systematic Review and Meta-Analysis

Malaria and Helminthic Co-Infection during Pregnancy in Sub-Saharan Africa: A Systematic Review and Meta-Analysis

Integration and application of new approach methodologies in assessing the developmental hazards: Case study with an antimalarial drug

Re-orienting anti-malarial drug development to better serve pregnant women

Contact Info

Product

Resources

About